DSM Biologics, a business unit of DSM Pharmaceutical Products (Parsippany, N.J.; www.dsmpharmaceuticalproducts.com) has signed a preliminary agreement to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility. The new biologics manufacturing facility, which will be located in Brisbane, is anticipated to be commissioned and operational in 2013.
The over 70,000-ft2 facility will offer mammalian process development and cGMP clinical and commercial manufacturing services. The Australian Governments will provide the full financial funding for the facility, which is part of the Queensland 10-yr Biotechnology Strategic Plan. DSM will provide no capital, but will provide technological expertise to design and set up the facilities and will employ its proprietary technologies in its operation.